Avista Capital Partners has agreed to buy pharma industry chemical and bioreagent specialist eMolecules, a month after closing its $1.2bn fifth fund.
Avista Capital Partners follows $1.2bn Fund V close with eMolecules buyout first appeared on AltAssets Private Equity News.